移植前移植物抗宿主病状态影响异基因造血干细胞移植后复发血液系统恶性肿瘤患者供者淋巴细胞输注的结局
该单中心回顾性研究分析了2015至2022年间56例因异基因造血干细胞移植后复发接受供者淋巴细胞输注的患者,探讨输注前有无移植物抗宿主病(GVHD)病史对输注后实现完全供者嵌合(FDC)及发生GVHD所带来的生存获益的影响。结果显示,仅在无GVHD病史的患者中,输注后实现FDC与1年总生存(OS)显著提高相关(73.7% vs 20.0%,p<0.001),发生GVHD后OS有升高趋势(60.0% vs 52.6%,p=0.067);而有GVHD病史者中未见显著差异。
要点
- 无GVHD病史者DLI后实现FDC的1年OS为73.7% vs 20.0%(p<0.001)。
- 无GVHD病史者DLI后发生GVHD的OS为60.0% vs 52.6%(p=0.067)。
- 有GVHD病史者DLI后实现FDC或发生GVHD均未显著改善OS。
核心结论
- DLI后实现FDC或发生GVHD可改善OS,但仅限于无GVHD病史的患者。
- 作者认为,无GVHD病史的患者可能更好地利用移植物抗白血病效应。
研究设计与样本
- 单中心回顾性分析,纳入2015至2022年在本研究所因alloHSCT后复发接受DLI的56例患者。
- 根据DLI前有无GVHD病史分组:无GVHD病史29例,有GVHD病史者另组。
主要发现
- 无GVHD病史组中,DLI后实现FDC者1年OS为73.7% vs 未实现者20.0%(p<0.001)。
- 无GVHD病史组中,DLI后发生GVHD者OS为60.0% vs 未发生者52.6%(p=0.067)。
- 有GVHD病史组中,实现FDC者OS为64.3% vs 未实现者33.3%(p=0.226)。
- 有GVHD病史组中,发生GVHD者OS为60.0% vs 未发生者53.3%(p=0.866)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimizing the effectiveness of donor lymphocyte infusion (DLI) for relapse after allogeneic stem cell transplantation (alloHSCT) has been challenging. We investigated whether the benefits of achieving full donor chimerism (FDC) and developing graft-versus-host disease (GVHD) after DLI are affected by a history of GVHD before DLI. We retrospectively analysed 56 patients who received DLI for relapse after alloHSCT at our institute from 2015 to 2022. Among 29 patients without GVHD before DLI, those who achieved FDC after DLI had a significantly higher 1-year overall survival (OS) compared to those who did not (73.7% vs. 20.0%; p < 0.001). Furthermore, in the same cohort, patients who developed GVHD after DLI showed a tendency towards higher OS compared to those who did not (60.0% vs. 52.6%; p = 0.067). In contrast, in patients with GVHD before DLI, there was no significant difference in OS between patients with or without achieving FDC (64.3% vs. 33.3%, p = 0.226) or developing GVHD (60.0% vs. 53.3%, p = 0.866). Our study showed that achieving FDC or developing GVHD after DLI improved OS, but only in those without a prior history of GVHD. The graft-versus-leukaemia effect may be better exploited in patients without a history of GVHD.
引用
- Velasco CM, Inoue Y, Cioccio J, et al. Prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation. Br J Haematol. 2025. PMID: 40534233. doi:10.1111/bjh.20215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。